Call for Demonstrator Projects



Similar documents
Insurance and compensation in the event of injury in Phase I clinical trials

Guidance notes on the management of adverse events and product complaints from digital media

Clinical Trial Compensation Guidelines

Chemicals and Life Sciences Industry Practice. Insurance and compensation in the event of injury in Phase I clinical trials in the United Kingdom

Industry Charter. Introduction. Context

The NHS as a Driver for Growth. A report by The Prime Minister s Council for Science and Technology

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies

Delivering in a challenging environment

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency

Request for Applications. Sharing Big Data for Health Care Innovation: Advancing the Objectives of the Global Alliance for Genomics and Health

A Strategy for Personal and Public Involvement (PPI) in Cancer Research in Northern Ireland

Wales Patient Access Scheme: Process Guidance

Data modelling methods in clinical trials: Experiences from the CTMND project (ctmnd.org)

DIGITAL COMMUNICATIONS

Accelerating Clinical Trials Through Shared Access to Patient Records

Guidance notes on the collection of adverse events and product complaints from market research programmes

Making Ontario a Preferred Location for Global Clinical Trials

Singapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY

Bringing Safe and Cost Effective Products to Market

Driver Diagram and Change Package Leadership and Culture. Primary Drivers

Foreword. Stephen Whitehead, Chief Executive, ABPI. Rt Hon Earl Howe, Parliamentary Under Secretary for Quality, Department of Health

Issue date: October Guide to the single technology appraisal process

SCR Expert Advisory Committee

NATIONAL INFORMATION BOARD. WORK STREAM 1.2 ROADMAP Enable me to make the right health and care choices


Ensuring Best Practice in the Notification of Product Discontinuations

60 Including some of the most influential public health thought leaders Prominent public health leaders and decision makers.

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

Information Governance. A Clinician s Guide to Record Standards Part 1: Why standardise the structure and content of medical records?

DIRECTORATE OF AUDIT, RISK AND ASSURANCE Internal Audit Service to the GLA

How GSK supports independent medical education

Center for Healthcare Transparency

Did you know? Accenture can deliver business outcome-focused results for your life sciences research & development organization like these:

Medical Science Liaison (MSL): Understanding, Engaging and Interacting. Gill Logan Regional Medical Affairs Manager Takeda UK

Best Practice Model. for the Disclosure of Results and Transparent Information on Clinical Trials

Sheffield Kidney Institute. Planning a Clinical Trial

I t erna ex ernal i nnova i o a d id our future Arloesi Mewnol ac Allanol i gynorthwyo ein dyfodol

Research Design Service London

Richard T. Clark Chief Executive Officer and President. Executing on Our Strategy

Specification Document (11/1023)

The amounts indicated excludes money spent by our partners where we co- promote products.

BUILDING A STRONGER SOCIETY SOCIAL IMPACT INVESTMENT February 2014 Submission in response to the Discussion Paper

COOPERATIVE RESEARCH CENTRES PROGRAMME REVIEW

Build Modern Apps with Today s BPM

Medical Information and Pharmacovigilance through acquisition. Lisa Hughes Medical Affairs Manager Actavis UK Ltd

An insight into careers for doctors. with the UK pharmaceutical industry

The new EU Clinical Trials Regulation How NHS research and patients will benefit

JOB DESCRIPTION. To assist in the formulation and delivery of psychological support plans under the supervision of a qualified Clinical Psychologist.

Deadline for entries Friday 3 rd July

A leader in the development and application of information technology to prevent and treat disease.

Product Life Cycle Management in Life Sciences Industry

Managing the boundaries of NHS and privately funded healthcare Policy on the separation of private and NHS treatments

Guidance linked to the model Industry Collaborative Research Agreement (micra)

FINANCIAL SYSTEM INQUIRY

Overview of the EHR4CR project Electronic Health Record systems for Clinical Research

HEALTH & WELL-BEING: AN EMPLOYER S PERSPECTIVE

Department for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

Research is everybody s business

Overview. Health Science Authority. Implementation of ICH guideline in Singapore. Singapore s experience

Prospect of ICT Utilization at Core Clinical Research Hospitals

Drug Information as part of Advanced Pharmacy Practice Experience

Transport for London. Projects and Planning Panel

Movember Clinical Trial Award (CTA)

Great Expectations: Why Pharma Companies Can t Ignore Patient Services

The Role of DrugDev in Modern Clinical Trials

Consultation Response Medical profiling and online medicine: the ethics of 'personalised' healthcare in a consumer age Nuffield Council on Bioethics

Leadership and Management Standards for Medical Professionals

Connected Health (Priority Area D)

Legislation to encourage medical innovation a consultation. British Medical Association response. Executive Summary

PUBLIC HEALTH LIMITED OPEN CALL SCHEME (LOCS) PHA202 RESEARCH BRIEFING

The 100,000 genomes project

Newton-Mosharafa PhD Programme

OPERATIONALIZING EXCELLENCE IN THE GLOBAL REGULATORY SUBMISSIONS PROCESS

Clinical Trial Transparency: Technical standards for data sharing for old, current and future clinical trials

Find the signal in the noise

TRANSFORMING LIFE SCIENCES THROUGH ENTERPRISE ANALYTICS

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

The Government plan for a secure data service

How does the NHS buy HIV Drugs?

NORWICH CLINICAL TRIALS UNIT OVERVIEW

EU Clinical Trials Register. An agency of the European Union

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Managing your Macmillan/Manchester Cancer Living With and Beyond Cancer Innovation Fund project

1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?

Workforce Race Equality Standard

Strong support. Remaining concerns

Policy for Care Quality Commission Essential standards of quality and safety self assessment and assurance process

Mobile Health in the Health Insurance Industry Kai-Lik Foh, Mobile Health Programme Manager, GSMA

Education Surveys and Trends for

Consultation on the development of a new IFS strategy. Yes

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care

Let the Potential of Your Business Emerge. Paragon Solutions Inc. Proprietary

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

ADVANCING POPULATION HEALTH: NEW MODELS AND THE ROLE OF RESEARCH

Supply Chain: improving performance in pricing, planning, and sourcing

Study-wide considerations: identifies the areas of the criterion the lead reviewer should consider when conducting the review

Rules & Entry Form. The 2O16 Man Booker International Prize Translated Fiction at its Finest

Self Care in New Zealand

Transcription:

Association of the British Pharmaceutical Industry 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT t +44 (0)870 890 4333 www.abpi.org.uk Call for Demonstrator Projects ABPI Big Data Demonstrators

Background In November 2013 the ABPI launched their big data road map document. This is a four-point plan to direct progress over the next four years. The four areas of focus in the plan are: increasing awareness; building capabilities and capacity; creating sustainable data ecosystems; and accelerating high-value opportunities. One of the big data road map actions is to accelerate high-value opportunities through the development of a demonstrator project portfolio, that showcases proof of concept projects of the application of big data techniques in areas such as genomics, interventional trials and observational studies, comparative effectiveness and value, and pharmacovigilance across the UK data ecosystem. We are seeking project examples of the innovative use of data either from projects that have already completed (retrospective), are in progress (current) or planned projects (future). This demonstrator project portfolio will seek to: 1. collect practical experiences in conducting big data activities as input for identifying and showcasing the current UK capabilities. 2. demonstrate big data activities to interested third parties in order to share experiences and best practice in the running of these activities. The ABPI will facilitate the showcase of these demonstrator projects to the pharmaceutical industry via its membership. UK organisations that are involved in big data activities are kindly asked to show their interest to act as a DEMONSTRATOR to enhance our practical view on the subject, as well as to show the broader global community about your activities. We believe that participation will provide you the opportunity to benefit from this, as participation will enhance the visibility of your organisation and activities and you will be at the forefront of the development of UK capabilities to support future work in this area. Scope Projects should aim to deliver an improvement in either medicine development or healthcare delivery and should involve novel methods of using patient data. See Appendix 1 for the types of projects we are interested in. As we seek to showcase the UK big data environment, demonstrator projects can come from a wide range of sources such as NHS organisations, businesses of any size, as well as academic organisations within the UK. 1

Submission Process The call for projects will be formally launched on the 22 May 2014. There is a rolling submission deadline for submitting projects of interest but we would seek to receive the attached Project of Interest template (see Appendix 2) no later than 12 August. This will allow us to contact shortlisted projects for on-going discussion to showcase the projects, including collections of key learning s and best practice no later than 1 September in the first instance. Completed forms should be sent to abpicomms@abpi.org.uk with the subject header Demonstrator Project of Interest. 2

Appendix 1 - What projects are we interested in? Projects should aim to deliver an improvement in either medicine development or healthcare delivery and should involve novel and/or innovative methods of using patient data or wider health data that demonstrate one or more of the following attributes: 1. Demonstrating innovative ways of leveraging existing health data sources such as: a. A novel method of linking data from one or more previously unlinked databases, at least one of which is a patient database. b. The ability to aggregate information from greater numbers of patients than has been achieved before in any therapeutic area. c. The ability to read aggregated results from two or more linked databases with greater statistical accuracy than has been achieved to date. d. A mechanism to link and/or search data in a novel way that can be replicated across differing types of database, and is scalable across different sizes and locations of databases. e. A novel method of linking data that can accommodate different coding systems that have been used in medical records to date, and enable accurate amalgamation of records. f. The capability to accommodate medical records from different languages, perhaps also including a novel type of translation tool. 2. An innovative project to gain benefit from existing health and wider data sources such as: a. The ability to create a longitudinal picture of the effect of a treatment regime on patients, giving data on adherence levels and outcomes. b. A novel use of linked patient data that has informed a beneficial development in trial design to achieve more accurate results. c. A novel use of linked patient data that demonstrates improved patient safety at any stage of the drug development process. d. The use of linked data to improve clinical decision making or commissioning, in terms of speed and accuracy of reviewing and recommending a particular treatment regime for patients. 3. An innovative project that develops data governance tools and frameworks for health data such as: a. A project that will leverage existing data governance arrangements and develop new frameworks for data governance. b. A project that will develop appropriate governance to protect personal data in smaller patient populations. 3

Appendix 2 - Projects of Interest template 1. Title 2. Summary of project (max 300 words). 3. What strategic questions did your project seek to address/explore and/or what was innovative about the projects? (max 250 words). 4. Which of the attributes in Appendix 1 did your project seek to address? 5. Which datasets are included in your project? 4